April 28, 2014 — JenaValve Technology Inc. – a privately held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems – announced it has secured an expansion to its Series C venture round of $10 million, increasing the total amount raised in the round from $62.5 million to $72.5 million.
New investors participating in the expansion of the round are U.K.-based Valiance Asset Management and Belgium-based RMM. Current investors participating in the financing round include Edmond de Rothschild Investment Partners; Atlas Venture Fund; NeoMed Management; VI Partners AG; Sunstone Capital A/S; Gimv (GIMB.EN), a publicly traded investment company; Legend Capital and Omega Funds.
The company also announced the addition of a new director and a board observer in conjunction with the financing round. Industry veteran Jan Keltjen was appointed to the JenaValve board of directors, effective Dec. 30, 2013. In addition, life sciences entrepreneur and financier Rudi Mariën was appointed as an observer to the board.
“JenaValve continues to build momentum in the European TAVI market with our novel transapical TAVI system,” said Helmut J. Straubiger, CEO of JenaValve Technology. “As we continue to work to gain clinical experience with our transfemoral TAVI system and build out international regulatory and commercial programs, we welcome the participation of new world-class investors and the governance and experience of Mr. Keltjens and Mr. Mariën as director and board observer, respectively.”
Mr. Keltjens is the chairman and CEO of Steering Brain Stimulation (Sapiens), a medical device company pioneering brain stimulation products. He has a strong track record in the medical device sector and more than 30 years of management experience, including the role of president and CEO of Endosense SA, which was acquired by St. Jude Medical in August 2013.
Mr. Mariën was co-founder, reference shareholder and chairman of Innogenetics, and has been the founder, shareholder and managing director of several clinical reference laboratories. Currently, he is managing director of Barc NV, an international centralized clinical laboratory exclusively dedicated to pharmaceutical studies.
For more information: www.jenavalve.com